Infinimmune has raised $75.0M in a Series A round, a significant infusion for a biotech startup with an unusually broad mission: treating human disease with truly human therapeutics. The company is betting that the key to better drugs lies in making them less foreign to the body, a concept that has long been a hurdle in the field.
The funding arrives as the company works to translate that idea into a pipeline of candidates. With a focus on developing therapies that mimic the body’s own immune responses, Infinimmune is positioning itself in a crowded but high-stakes space where differentiation often comes down to how closely a treatment can mirror natural biology. The round’s size suggests investor conviction in that approach, though the company has not disclosed who is backing the effort.
.png&w=3840&q=75)
